Plant Name: Dalbergia sissoo
Taxonomic Information:
Plant ID: NPO1830
Plant Latin Name: Dalbergia sissoo
Taxonomy Genus: Dalbergia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
107308
Plant-of-the-World-Online:
490469-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Sowa-Rigpa; TCM; Unani; Ayurveda; SiddhaGeographical Distribution:
Brazil; Afghanistan; Bangladesh; Sudan; Guinea; Nepal; Nigeria; Cameroon; Malawi; Benin; Ghana; Australia; Iran; Cuba; Zambia; Burkina Faso; Togo; Zimbabwe; China; Dominican Republic; Iraq; Sierra Leone; Mauritania; Oman; Tanzania; Indonesia; United States; Guinea-Bissau; Taiwan; Pakistan; Myanmar; Chad; India; Senegal; Mozambique; Uganda; Kenya; Niger
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPER1; | |
| TSHR; | |
| BLM; AOX1; | |
| ACHE; | |
| EGFR; | |
| CA2; CA7; CA4; CA12; | |
| AR; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| SHBG; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Small molecule receptor (family A GPCR) | GPER1 | G-protein coupled estrogen receptor 1 | Q99527 | CHEMBL5872 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.334E-14 | 2.904E-10 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, GPER1, SHBG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.132E-09 | 3.522E-06 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.080E-09 | 5.661E-06 | AR, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.818E-08 | 8.071E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.105E-07 | 1.718E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.136E-07 | 6.578E-04 | AR, ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.019E-06 | 1.167E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 1.135E-06 | 1.235E-03 | AR, ESR1, ESR2, GPER1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.054E-06 | 2.891E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0071392; cellular response to estradiol stimulus | 6.083E-06 | 4.153E-03 | EGFR, ESR1, GPER1 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 6.104E-06 | 4.153E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 4.153E-03 | CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 6.104E-06 | 4.153E-03 | AR, SHBG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.524E-05 | 8.969E-03 | CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.716E-09 | 1.201E-07 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.575E-06 | 9.012E-05 | GPER1, ESR1, EGFR, ESR2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.590E-05 | 7.517E-04 | CYP2C9, AOX1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.296E-05 | 7.517E-04 | CYP2C9, AOX1, CYP3A4 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.374E-04 | 3.323E-03 | CA2, CA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.795E-04 | 4.428E-03 | CYP2C9, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; AR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; AR; ACHE; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; AR; EGFR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; AR; EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; AR; ACHE; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; AR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; AR; ESRRA; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; AR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; AR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
